NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors were
found to decrease in the frontal lobe and hippocampus of mild cognitive impairment. This
study is a randomized, double-blind, placebo-controlled drug trial. All subjects will be
allocated randomly to 2 groups: (1) NMDA-enhancer: DAOIB group (starting dose: 250-500 mg/d);
(2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOIB may
yield better efficacy than placebo for cognitive function in patients with mild cognitive
impairment.